News and Trends 2 Feb 2023
AstraZeneca creates FRAGLER for DNA synthesis
“Plasmids are critical for so many processes in early drug discovery,” says David Öling, associate principal scientist at AstraZeneca. “From…
AstraZeneca
- Latest Posts
News and Trends 26 Jan 2023
Ibex to collaborate with AstraZeneca and Daiichi Sankyo on AI breast cancer product
Ibex Medical Analytics has announced an agreement with AstraZeneca and Daiichi Sankyo, for the development, clinical validation and early adoption…
News and Trends 20 Jan 2023
Beyond Biotech podcast 30: Advanced Therapies Congress, BioAlps, Bionter, C2i Genomics
The guests on our podcast this week are: Jessica Robinson, project director, Advanced Therapies Congress, Terrapinn: Tobias Werk, CEO, Bionter;…
News and Trends 11 Jan 2023
AstraZeneca’s Airsupra gets US approval as new rescue treatment for asthma
Avillion LLP says the US Food and Drug Administration (FDA) has approved AstraZeneca’s Airsupra for the as-needed treatment or prevention…
ADVERTISEMENT
News and Trends 6 Jan 2023
C2i Genomics extends AstraZeneca cancer deal
C2i Genomics, a cancer intelligence company, today announced an extension of a collaboration with AstraZeneca. The two companies have collaborated…
News and Trends 9 Dec 2022
New targeted drug shows benefit against breast cancer in first phase III trial
A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase…
News and Trends 9 Dec 2022
Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene
This week, we have three interviews. One is from Bio-Europe, a chat with Transgene chief business officer, Steven Bloom, and…
More News! 8 Dec 2022
Enhertu’s positive results demonstrate improvement in overall survival
Enhertu, an antibody drug conjugate, being jointly developed by Daiichi Sankyo and AstraZeneca, has demonstrated a statistically significant and clinically…
News and Trends 30 Nov 2022
AstraZeneca splashes out up to $320M on T-cell receptor therapy company
Neogene Therapeutics, Inc., a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts),…
News and Trends 28 Nov 2022
Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca
C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca. It is worth up to $402 million, for…
ADVERTISEMENT
News and Trends 18 Nov 2022
AstraZeneca and Daiichi Sankyo’s Enhertu recommended for approval
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) for patients previously treated HER-2 positive advanced…
Interview 14 Nov 2022
In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus
AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus…
More News! 4 Nov 2022
Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved
A drug being developed jointly by Sanofi and AstraZeneca for the prevention of respiratory syncytial virus (RSV) lower respiratory tract…
News and Trends 11 Oct 2022
Illumina and AstraZeneca look to drug target discovery with ‘pivotal research collaboration’
Illumina Inc. has announced a strategic research collaboration with AstraZeneca to accelerate drug target discovery by combining their work in…
News and Trends 4 Oct 2022
ASPIRE set up to collaborate on amyloidosis
A new group of biotech and pharma companies has been assembled by the Amyloidosis Research Consortium (ARC). ASPIRE (amyloidosis stakeholder…
News and Trends 3 Oct 2022
Alexion, AstraZeneca Rare Disease to acquire genomic medicine company LogicBio Therapeutics
LogicBio Therapeutics, Inc. has entered into a definitive agreement under which Alexion, AstraZeneca Rare Disease (Alexion) will acquire LogicBio. The…
ADVERTISEMENT
News and Trends 16 Sep 2022
CHMP recommends approval of Beyfortus for prevention of RSV disease in infants
Beyfortus, which is being developed jointly by Sanofi and AstraZeneca, is a step closer to preventing respiratory syncytial virus (RSV)…
News and Trends 7 Sep 2022
Ionis presents positive study results at International Symposium on amyloidosis
Ionis Pharmaceuticals, Inc. has presented positive results from a planned 35-week interim analysis of the phase 3 NEURO-TTRansform study of…
News and Trends 11 Aug 2022
Acquisition of TeneoTwo and its clinical-stage T-cell engager completed
AstraZeneca has said today (August 11) that it has completed its purchase of TeneoTwo including its B-cell non-Hodgkin lymphoma drug…
News and Trends 8 Aug 2022
Lung cancer trial patients responding well to combination treatment offered by HUTCHMED and AstraZeneca
A medication used to treat non-small cell lung carcinomas (NSCLC) with specific mutations has demonstrated a 49% objective response rate…